Drug recall · January 3, 2024
Jardiance recall
Why: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Jardiance (empagliflozin tablets), 25 mg, 30 tablets (3 blister cards with 10 tablets each), Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877. NDC: 0597-0153-37
- Lots / codes
Batch D41919
- Quantity
- 1 unit
- Company
- Cardinal Healthcare, Dublin, OH
- Distribution
- Nationwide USA
- Initiated
- January 26, 2022 · Voluntary: Firm initiated
- Classified
- December 26, 2023
- Reported
- January 3, 2024
- Ended
- September 29, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Jardiance
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.